Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery

Stefan Huttenlocher; Lena Sehmisch; Steven E Schild; Oliver Blank; Dagmar Hornung; Dirk Rades

Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery

Standard

Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. / Huttenlocher, Stefan; Sehmisch, Lena; Schild, Steven E; Blank, Oliver; Hornung, Dagmar; Rades, Dirk.

In: ANTICANCER RES, Vol. 34, No. 10, 10.2014, p. 5589-92.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Huttenlocher, S, Sehmisch, L, Schild, SE, Blank, O, Hornung, D & Rades, D 2014, 'Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery', ANTICANCER RES, vol. 34, no. 10, pp. 5589-92.

APA

Huttenlocher, S., Sehmisch, L., Schild, S. E., Blank, O., Hornung, D., & Rades, D. (2014). Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. ANTICANCER RES, 34(10), 5589-92.

Vancouver

Huttenlocher S, Sehmisch L, Schild SE, Blank O, Hornung D, Rades D. Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery. ANTICANCER RES. 2014 Oct;34(10):5589-92.

Bibtex

@article{f09986ece033463bbbe6a1aceee3c93c,

title = "Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery",

abstract = "BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases.PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10.RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001).CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT).",

keywords = "Aged, Aged, 80 and over, Brain Neoplasms, Combined Modality Therapy, Cranial Irradiation, Female, Humans, Male, Melanoma, Middle Aged, Prognosis, Radiosurgery, Retrospective Studies, Treatment Outcome",

author = "Stefan Huttenlocher and Lena Sehmisch and Schild, {Steven E} and Oliver Blank and Dagmar Hornung and Dirk Rades",

year = "2014",

month = oct,

language = "English",

volume = "34",

pages = "5589--92",

journal = "ANTICANCER RES",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

RIS

TY - JOUR

T1 - Identifying melanoma patients with 1-3 brain metastases who may benefit from whole-brain irradiation in addition to radiosurgery

AU - Huttenlocher, Stefan

AU - Sehmisch, Lena

AU - Schild, Steven E

AU - Blank, Oliver

AU - Hornung, Dagmar

AU - Rades, Dirk

PY - 2014/10

Y1 - 2014/10

N2 - BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases.PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10.RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001).CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT).

AB - BACKGROUND/AIM: To develop a tool for estimating the risk of developing new cerebral lesions in 69 melanoma patients receiving radiosurgery for 1-3 cerebral metastases.PATIENTS AND METHODS: Ten factors were investigated: lactate dehydrogenase (LDH), radiosurgery dose, age, gender, performance status, maximum diameter, location and number of cerebral lesions, extra-cranial spread, time between melanoma diagnosis and radiosurgery. Two factors, number of lesions and extra-cranial spread, were included in the tool. Scoring points were achieved by dividing the 6-month rate of freedom from new cerebral lesions by 10.RESULTS: Sum scores were 9, 11, 12 or 14 points. Six-month rates of freedom from new brain metastases were 28%, 63%, 59% and 92% (p=0.002). Three prognostic groups were designed: A (9 points), B (11-12 points) and C (14 points). Freedom from new cerebral lesion rates were 28%, 60% and 92% (p<0.001).CONCLUSION: Group A and B patients should be considered for additional whole-brain radiotherapy (WBRT).

KW - Aged

KW - Aged, 80 and over

KW - Brain Neoplasms

KW - Combined Modality Therapy

KW - Cranial Irradiation

KW - Female

KW - Humans

KW - Male

KW - Melanoma

KW - Middle Aged

KW - Prognosis

KW - Radiosurgery

KW - Retrospective Studies

KW - Treatment Outcome

M3 - SCORING: Journal article

C2 - 25275060

VL - 34

SP - 5589

EP - 5592

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 10

ER -